Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Adipocyte-specific ablation of the Ca 2+ pump SERCA2 impairs whole-body metabolic function and reveals the diverse metabolic flexibility of white and brown adipose tissue

Bauzá-Thorbrügge M., Banke E., Chanclón B., Peris E., Wu Y., Musovic S.

Prospective Study on Systemic / IV, published in Mol Metab (2022) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Mol Metab (2022)
Reported sample size
—
Source database
Europe PMC
PMID
35760318
PMCID
PMC9287368
DOI
10.1016/j.molmet.2022.101535
Citations
12

Abstract (original English)

Objective Sarco/endoplasmic reticulum Ca 2+ -ATPase (SERCA) transports Ca 2+ from the cytosol into the endoplasmic retitculum (ER) and is essential for appropriate regulation of intracellular Ca 2+ homeostasis. The objective of this study was to test the hypothesis that SERCA pumps are involved in the regulation of white adipocyte hormone secretion and other aspects of adipose tissue function and that this control is disturbed in obesity-induced type-2 diabetes. Methods SERCA expression was measured in isolated human and mouse adipocytes as well as in whole mouse adipose tissue by Western blot and RT-qPCR. To test the significance of SERCA2 in adipocyte functionality and whole-body metabolism, we generated adipocyte-specific SERCA2 knockout mice. The mice were metabolically phenotyped by glucose tolerance and tracer studies, histological analyses, measurements of glucose-stimulated insulin release in isolated islets, and gene/protein expression analyses. We also tested the effect of pharmacological SERCA inhibition and genetic SERCA2 ablation in cultured adipocytes. Intracellular and mitochondrial Ca 2+ levels were recorded with dual-wavelength ratio imaging and mitochondrial function was assessed by Seahorse technology. Results We demonstrate that SERCA2 is downregulated in white adipocytes from patients with obesity and type-2 diabetes as well as in adipocytes from diet-induc

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AnimalsHumansMiceDiabetes Mellitus, Type 2ObesityHormonesGlucoseAdipose Tissue, BrownAdipocytes, Brown

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research